AirSculpt Technologies, Inc.

AIRS Healthcare Medical Care Facilities

AirSculpt Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $151.8 million, down 15.8% from fiscal 2024. In the quarter to June 2026, revenue fell 2.53%, EPS fell 57.0%, free cash flow fell 131.1% and total debt fell 24.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.28 0.14 −9.86%
Market cap
$102.0M
P/E
0.0×
Fwd P/E
−63.9×
Dividend yield
—
F-score
3/9
Altman Z
0.94
Beneish M
−3.34
Dividend safety
n/a

Insider Decisions trades per month

Total buys 1.80
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — 7 4 — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 85.22%

Capital & Financial Ratios $m

Market Cap 102.02
Revenue 150.72
Net Income (11.74)
Free Cash Flow 0.76
Net Debt 24.74
Current Ratio 0.79 (below 1: weak)
Debt/Equity 0.42 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (63.90) (negative: loss-making)
P/S ratio 0.60
P/B ratio 0.86
Past 5Y EPS Growth —
This Y EPS Growth (60.00%) (below 0%: weak)
Next Y EPS Growth 43.75% (at or above 15%: strong)
Next Y revenue growth (0.54%) (below 0%: weak)
Next 5Y EPS Growth 11.21%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/S against its own 10 years 0.56%
10-year low 10-year high
P/B against its own 10 years 0.08%
10-year low 10-year high
EV/Sales against its own 10 years 0.08%
10-year low 10-year high
EV/FCF against its own 10 years 76.41%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2024 Powerpack
2023 Powerpack
2022 0.00
0.41
2021 Powerpack
2020 Powerpack
2019 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 10 8 8 19
Receivables 2 3 1 2
Inventory — — — —
Other — — — —
16 17 15 27
2023 2024 2025 Q'26
Payables 4 6 5 7
ST’ Debt 2 4 5 10
Other — — — —
20 29 28 35

Compound Annual Growth %

10y 5y 3y
Sales — 19.32% (3.47%)
Cash Flow — (26.01%) (49.78%)
Earnings — 0.00% 0.00%
Book Value — (6.64%) 7.42%

Revenue $m

Mar Jun Sep Dec Year
’26 39 43 — — —
’25 39 44 35 33 152
’24 48 51 43 39 180
’23 46 56 47 48 196
’22 40 50 39 41 169
’21 26 35 35 38 133
’20 — — 18 23 63
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 5 (1) — — —
’25 1 5 0 (3) 3
’24 3 3 2 3 11
’23 6 12 1 5 24
’22 7 10 0 7 24
’21 9 15 9 (6) 27
’20 — — — 14 14
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 5 (1) — — —
’25 (1) 5 0 (3) 1
’24 2 (1) (3) (1) (3)
’23 2 10 (1) 3 14
’22 3 9 (4) 4 12
’21 8 13 7 (8) 20
’20 — — — 10 10
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.03) (0.02) — — —
’25 (0.05) (0.01) (0.15) 0.02 (0.19)
’24 0.10 (0.06) (0.10) (0.09) (0.14)
’23 0.00 0.03 (0.03) (0.08) (0.08)
’22 (0.01) 0.01 (0.13) (0.13) (0.26)
’21 — — — — (0.01)
’20 — — — — 0.14
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — — 9.83 2.69 3.60 2.92 1.53

Analyst estimates 2026–2028

Powerpack
High — — — — — 18.48 17.54 9.94 9.20 12.00
People
People Employees — — — — 260 268 302 381 422 363
Revenue/emp, $m — — — 0.00 0.24 0.50 0.56 0.51 0.43 0.42
Income, $m
Income, $m Revenue — — — 41 63 133 169 196 180 152
Gross margin, % — — — 62.44 62.61 66.59 62.81 62.34 60.55 59.37
EBT — — — (2) 8 11 (11) 3 (8) (18)
EBT margin, % — — — (5.36) 12.07 8.16 (6.69) 1.65 (4.34) (11.62)
Net income — 0 — (2) 8 11 (15) (4) (8) (12)
Depreciation — — — 5 6 7 8 10 12 13
Per share, $
Per share, $ Revenue — — — 0.74 1.13 2.40 3.03 3.45 3.13 2.51
Earnings — — — (0.04) 0.14 (0.01) (0.26) (0.08) (0.14) (0.19)
Cash flow — — — 0.09 0.25 0.48 0.44 0.42 0.20 0.05
Capex — — — (0.08) (0.07) (0.13) (0.23) (0.17) (0.24) (0.04)
Free cash flow — — — 0.01 0.18 0.35 0.21 0.25 (0.05) 0.01
Book value — — — 2.16 2.22 1.50 1.27 1.48 1.36 1.45
Shares, m — — — 56 56 56 56 57 58 60
Valuation, ×
Valuation, × P/E — — — 33.81 33.81 0.00 0.00 0.00 0.00 0.00
P/S — — — 7.45 7.45 7.17 1.22 2.08 1.66 0.79
P/B — — — 0.00 0.00 11.45 2.92 4.86 3.83 1.36
EV/Sales — — — 8.31 8.31 7.60 1.66 2.40 2.03 1.10
EV/FCF — — — 26.02 26.02 51.94 24.34 33.45 (137.70) 241.75
Cash, $m
Cash, $m Operating cash flow — — — 5 14 27 24 24 11 3
Capex — — — (4) (4) (7) (13) (10) (14) (2)
Free cash flow — — — 0 10 20 12 14 (3) 1
Balance, $m
Balance, $m Working capital — — — (2) 2 13 (6) (4) (12) (12)
Total debt — — — 33 33 83 84 72 75 56
Net debt — — — 28 22 57 74 61 66 48
Shareholders’ equity — — — 120 124 84 71 84 78 88
Returns, %
Returns, % ROA — — — (2.58) 4.32 (0.21) (7.32) (2.09) (3.85) (5.83)
ROIC — — — 0.28 4.30 7.00 (1.96) 4.18 (0.68) (5.34)
ROE — — — (1.81) 6.21 (0.38) (19.03) (5.48) (9.89) (14.07)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

AirSculpt Technologies, Inc. vs peers in Medical Care Facilities (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
AUNA Auna S.A. $392.3M 76.0× 5.2× +20.51% (above 0%: growing) −61.29% (below 0%: shrinking) +121.08% (above 0%: growing) 35.72% 13.09% Compare
SRTA Strata Critical Medical, Inc. $384.0M 9.0× — (loss-making) +60.74% (above 0%: growing) n/m +150.33% (above 0%: growing) 20.98% (7.46%) Compare
AIRS AirSculpt Technologies, Inc. $102.0M — (loss-making) — (loss-making) −2.53% (below 0%: shrinking) n/m −131.07% (below 0%: shrinking) 61.38% (0.07%)
JYNT The Joint Corp. $97.7M 26.0× 16.9× +14.41% (above 0%: growing) +400.00% (above 0%: growing) +432.31% (above 0%: growing) 83.68% (2.43%) Compare
PARK Park Dental Partners, Inc. $91.3M — (loss-making) — +12.15% (above 0%: growing) −65.84% (below 0%: shrinking) −34.78% (below 0%: shrinking) 14.37% 1.90% Compare
BTMD biote Corp. $39.9M 6.8× 11.0× −9.48% (below 0%: shrinking) n/m −174.16% (below 0%: shrinking) 65.38% (7.93%) Compare
PIII P3 Health Partners Inc. $30.1M — (loss-making) — +8.60% (above 0%: growing) n/m −272.24% (below 0%: shrinking) 22.26% 10.67% Compare
CCEL Cryo-Cell International Inc. $29.4M — (loss-making) 43.8× −0.02% (below 0%: shrinking) +77.78% (above 0%: growing) −58.37% (below 0%: shrinking) 79.38% 28.04% Compare
DCGO DocGo Inc. $27.9M — (loss-making) — (loss-making) −8.70% (below 0%: shrinking) n/m −132.28% (below 0%: shrinking) 30.52% (24.41%) Compare
Median of peers $65.6M 17.5× 14.0× +10.38% +8.25% −46.57% 33.12% (0.26%)

All 55 Medical Care Facilities stocks →

AirSculpt Technologies, Inc. (AIRS) key facts

  • Concern: AirSculpt Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $151.8 million, down 15.8% from fiscal 2024.
  • AirSculpt Technologies, Inc. (AIRS) is a Medical Care Facilities company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, AIRS traded at $1.28, a market capitalization of $102.0 million.
  • Return on equity was −14.1% and debt-to-equity 0.42.
  • Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 0.94 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

AirSculpt Technologies, Inc. (AIRS) Latest News

2 May

Impact 4 · transcript

14 Apr

26 Mar

15 Mar

Impact 4 · transcript
stockrow.com/AIRS · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com